Get the Stockscreener App
28.12
0.38%
-0.42
Biodesix Inc stock is traded at $28.12, with a volume of 76,606.
It is down -0.38% in the last 24 hours and up +14.98% over the past month.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
See More
Previous Close:
$27.70
Open:
$27.77
24h Volume:
76,606
Relative Volume:
0.79
Market Cap:
$296.75M
Revenue:
$96.10M
Net Income/Loss:
$-31.96M
P/E Ratio:
-6.9834
EPS:
-4.0267
Net Cash Flow:
$-25.27M
1W Performance:
+1.90%
1M Performance:
+14.98%
6M Performance:
+59.60%
1Y Performance:
+320.66%
1-Day Range:
$27.55
$29.00
1-Week Range:
$25.60
$29.00
52-Week Range:
$5.26
$31.31
Biodesix Inc Stock (BDSX) Company Profile
Name
Biodesix Inc
Sector
Industry
Phone
303-417-0500
Address
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX vs TMO, DHR, NTRA, IQV, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
28.12 | 284.51M | 96.10M | -31.96M | -25.27M | -4.0267 |
TMO
Thermo Fisher Scientific Inc
|
650.13 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
209.01 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
344.62 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
269.32 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
153.64 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-26-24 | Initiated | Craig Hallum | Buy |
| May-13-24 | Initiated | TD Cowen | Buy |
| May-03-24 | Initiated | Lake Street | Buy |
| Nov-17-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-23-20 | Initiated | BTIG Research | Buy |
| Nov-23-20 | Initiated | Canaccord Genuity | Buy |
| Nov-23-20 | Initiated | Morgan Stanley | Overweight |
| Nov-23-20 | Initiated | William Blair | Outperform |
View All
Biodesix Inc Stock (BDSX) Latest News
A Look at Biodesix Inc (BDSX) After 3.5% Gain -- GF Value $21.14 vs Price $26.96 - GuruFocus
Opaleye Management Inc. Cuts Position in Biodesix, Inc. $BDSX - marketbeat.com
Biodesix: Growing Fast While Trading Below Many Diagnostics Peers (NASDAQ:BDSX) - Seeking Alpha
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Recommendation of "Moderate Buy" by Analysts - marketbeat.com
BlackRock Inc. Invests $970,000 in Biodesix, Inc. $BDSX - marketbeat.com
Biodesix Stock Price Forecast. Should You Buy BDSX? - StockInvest.us
Biodesix to Participate in Upcoming Investor Conferences - The Manila Times
Biodesix Inc (NASDAQ: BDSX) Stock Price, News & Analysis - kalkine.ca
BioDesix (NASDAQ:BDSX) Passes Minervini Trend Template but Setup Quality Remains Weak - ChartMill
What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Biodesix Inc (BDSX) Stock Up 9.0% but GF Value Says Overvalued -- GF Score: 51/100 - GuruFocus
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect? - qz.com
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? - The Globe and Mail
Biodesix (BDSX) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Stock Loses 5.91% in the Latest SessionCEO Earnings Statement - vinanet.vn
Biodesix (BDSX) Results Check: The Bottom-Line Figure Beats Its Comparison; After Earnings: The Market Price Declines 3.91% in Latest TradingGuidance Accuracy Score - vinanet.vn
46,989 Shares in Biodesix, Inc. $BDSX Purchased by GSA Capital Partners LLP - MarketBeat
AIGH Capital Management LLC Acquires New Stake in Biodesix, Inc. $BDSX - MarketBeat
Biodesix (BDSX) Edges Higher at $24.0 as Bulls Defend Key SupportVol Target Rebalance - vinanet.vn
Walleye Capital LLC Makes New $1.68 Million Investment in Biodesix, Inc. $BDSX - MarketBeat
Sei Investments Co. Makes New Investment in Biodesix, Inc. $BDSX - MarketBeat
BDSX Q2 2026 Earnings: EPS Beats Estimates by 22.85% as Loss NarrowsEarnings Preview - vinanet.vn
BDSX | Biodesix, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Biodesix director Jack Schuler buys company stock, valued at $366,991 By Investing.com - Investing.com Australia
Biodesix director Jack Schuler buys company stock, valued at $366,991 - Investing.com
BDSX Q2 2026 Earnings: Narrower Loss Beats Estimates as Shares Dip 1.78Earnings Yield Spread - Vinanet
Biodesix (NASDAQ:BDSX) Director Jack Schuler Buys 15,000 Shares of Stock - MarketBeat
Biodesix Insider Bought Shares Worth $366,992, According to a Recent SEC Filing - marketscreener.com
Biodesix Inc (BDSX) major holder Jack W. Schuler buys 15,000 shares - Stock Titan
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Biodesix director Jack Schuler buys $665,940 in company stock By Investing.com - Investing.com Australia
Biodesix (NASDAQ:BDSX) Director Jack Schuler Purchases 13,700 Shares of Stock - MarketBeat
Insider Buying: Biodesix (NASDAQ:BDSX) Director Purchases 13,900 Shares - MarketBeat
Biodesix director Jack Schuler buys $665,940 in company stock - Investing.com India
Biodesix at Canaccord Genuity conference: growth, margins in focus By Investing.com - Investing.com Nigeria
Biodesix (BDSX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Biodesix (BDSX) major holder Jack W. Schuler adds shares via trusts - Stock Titan
Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference - TradingView
Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Canaccord raises Biodesix stock price target on strong test volume By Investing.com - Investing.com India
Wall Street Analysts Think Biodesix (BDSX) Could Surge 31.91%: Read This Before Placing a Bet - Yahoo Finance
BDSX Maintained by Canaccord Genuity -- Price Target Raised to $35 - GuruFocus
Canaccord Genuity Group Issues Positive Forecast for Biodesix (NASDAQ:BDSX) Stock Price - MarketBeat
Canaccord raises Biodesix stock price target on strong test volume - Investing.com India
HC Wainwright Forecasts Biodesix's Q3 Earnings (NASDAQ:BDSX) - MarketBeat
Earnings Update: Here's Why Analysts Just Lifted Their Biodesix, Inc. (NASDAQ:BDSX) Price Target To US$32.67 - webull.com
H.C. Wainwright Maintains Biodesix(BDSX.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Biodesix Inc (BDSX) Stock News Today - TradingKey
Biodesix boosts sales, trims loss as diagnostics firm pushes toward profitability - BizWest
A Quick Look at Today's Ratings for Biodesix(BDSX.US), With a Forecast Between $27 to $40 - Moomoo
Analysts Offer Insights on Healthcare Companies: Biodesix (BDSX), Pacific Biosciences (PACB) and Odyssey Therapeutics, Inc. (ODTX) - The Globe and Mail
BDSX Maintains Buy Rating -- Price Target Raised to $27.00 by HC Wainwright - GuruFocus
Biodesix Inc Stock (BDSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
4.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):